Diligence memo · auto-generated · as of July 2, 2026
Arisaph Pharmaceuticals Inc
Arisaph Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Arisaph Pharmaceuticals Inc operates in Pharmaceuticals, based in BOSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Arisaph Pharmaceuticals Inc has raised $10M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2013-10-17.
Most recent recorded round closed around 2013-10-17.
Valuation (modeled)modeled
Provath models Arisaph Pharmaceuticals Inc at approximately $310M (range $11M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.58× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 54% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.